D
Cogent Biosciences, Inc. COGT
$36.68 -$2.85-7.21% NASDAQ
Recommendation
Prev Close
$36.68
Volume
3,068,155
Avg Vol (90D)
2,976,052
Market Cap
$5.58B
Dividend & Yield
--
52-Week Range
$3.72 - $43.73
P/E (TTM)
--
EPS (TTM)
-$2.47
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages
1/24/2026 - MarketBeat
Real-Time FDA Review Of Bezuclastinib Combo In GIST Might Change The Case For Investing In Cogent Biosciences (COGT)
1/23/2026 - Simply Wall St
Fairmount Funds Management Llc Sells 3,500,000 Shares of Cogent Biosciences (NASDAQ:COGT) Stock
1/23/2026 - MarketBeat
Emerald Mutual Fund Advisers Trust Grows Position in Cogent Biosciences, Inc. $COGT
1/23/2026 - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Director Fairmount Funds Management Llc Sells 3,500,000 Shares
1/23/2026 - MarketBeat
Emerald Advisers LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT
1/22/2026 - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Earns Outperform Rating from Wedbush
1/21/2026 - MarketBeat
Wedbush Reiterates "Outperform" Rating for Cogent Biosciences (COGT) COGT Stock News
1/21/2026 - GuruFocus
A Look At Cogent Biosciences (COGT) Valuation After FDA Accepts Bezuclastinib NDA Under RTOR Program
1/21/2026 - Simply Wall St
FDA Greenlights Cogent Biosciences' New Drug Application for GIST Treatment
1/20/2026 - GuruFocus
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
1/20/2026 - Globe Newswire
Campbell & CO Investment Adviser LLC Purchases Shares of 61,634 Cogent Biosciences, Inc. $COGT
1/20/2026 - MarketBeat
Cogent Biosciences (COGT, $38.94) Moving Average Convergence Divergence (MACD) Histogram turned positive on January 16, 2026
1/17/2026 - Tickeron - Stocks
Why Cogent Biosciences (COGT) Is Up 10.3% After Mapping Bezuclastinib's Multi-Indication NDA Strategy
1/16/2026 - Simply Wall St
Cogent Biosciences (NASDAQ:COGT) Shares Up 7.1% - Still a Buy?
1/14/2026 - MarketBeat
Cogent Biosciences, Inc. (COGT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
1/13/2026 - Seeking Alpha: Transcripts
Cogent Biosciences, Inc. (COGT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
1/13/2026 - SeekingAlpha
Cogent Biosciences Inc at JPMorgan Healthcare Conference Transcript
1/13/2026 - GuruFocus
Cogent Biosciences, Inc. (COGT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
1/13/2026 - SeekingAlpha
Cogent Biosciences announces anticipated 2026 commercial, clinical milestones
1/12/2026 - The Fly
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for ...
1/12/2026 - GuruFocus
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
1/12/2026 - Globe Newswire
Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge
1/11/2026 - Nasdaq News: Markets
Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge
1/11/2026 - Fool.com Headlines
H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT)
1/11/2026 - Insider Monkey
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$305.04M
EBIT (TTM)
-$307.60M
Net Income (TTM)
-$294.37M
Balance Sheet
Total Assets (Q)
$425.93M
Total Debt (Q)
$60.56M
Total Liabilities (Q)
$123.47M
Book Value Per Share (Q)
$1.39
Cash Flow
Cash from Operations (TTM)
-$245.92M
Cash from Investing (TTM)
-$15.09M
Cash from Financing (TTM)
$289.59M
Net Change in Cash (TTM)
$28.59M
Filings
Filing Date
Friday, November 7, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
0.97
7-Day Total Return
-2.94%
30-Day Total Return
-6.36%
60-Day Total Return
127.97%
90-Day Total Return
192.50%
Year to Date Total Return
5.58%
1-Year Total Return
339.28%
2-Year Total Return
727.99%
3-Year Total Return
150.55%
5-Year Total Return
234.67%
52-week Low
Apr 09, 2025 - $3.72
52-week High
Dec 08, 2025 - $43.73
Valuation
Market Cap
$5.58B - Mid Cap
Enterprise Value
$5.36B
Price/Sales (TTM)
--
Price/Book (Q)
26.38
Dividends and Shares
Shares Outstanding
137.62M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.cogentbio.com
Phone Number
617 945 5576
Address
275 Wyman Street
Waltham, MA 02451
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a... more
NASDAQ 01/23/2026 4:00PM Eastern Quotes delayed